A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes
R Brian Stevens, Kirk W Foster, Clifford D Miles, James T Lane, Andre C Kalil, Diana F Florescu, John P Sandoz, Theodore H Rigley, Kathleen J Nielsen, Jill Y Skorupa, Anna M Kellogg, Tamer Malik, Lucile E Wrenshall, R Brian Stevens, Kirk W Foster, Clifford D Miles, James T Lane, Andre C Kalil, Diana F Florescu, John P Sandoz, Theodore H Rigley, Kathleen J Nielsen, Jill Y Skorupa, Anna M Kellogg, Tamer Malik, Lucile E Wrenshall
Abstract
Background: We conducted a randomized and unblinded 2 × 2 sequential-factorial trial, composed of an induction arm (part 1) comparing single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a maintenance arm (part 2) comparing tacrolimus minimization versus withdrawal. We report the long-term safety and efficacy of SD-rATG induction in the context of early steroid withdrawal and tacrolimus minimization or withdrawal.
Methods: Patients (n=180) received 6 mg/kg rATG, SD or four alternate-day doses (1.5 mg/kg/dose), with early steroid withdrawal and tacrolimus or sirolimus maintenance. After 6 months targeted maintenance levels were tacrolimus, 2 to 4 ng/mL and sirolimus, 4 to 6 ng/mL or, if calcineurin inhibitor-withdrawn, sirolimus 8 to 12 ng/mL with mycophenolate mofetil 2 g two times per day. Primary endpoints were renal function (abbreviated modification of diet in renal disease) and chronic graft histopathology (Banff). Secondary endpoints included patient survival, graft survival, biopsy-proven rejection, and infectious or noninfectious complications.
Results: Follow-up averaged longer than 4 years. Tacrolimus or sirolimus and mycophenolate mofetil exposure was identical between groups. The SD-rATG associated with improved renal function (2-36 months; P<0.001) in deceased donor recipients. The SD-rATG associated with quicker lymphocyte, CD4 T cell, and CD4-CD8 recovery and fewer infections. Cox multivariate hazard modeling showed divided-dose-rATG (P=0.019), deceased donor (P=0.003), serious infection (P=0.0.018), and lower lymphocyte count (P=0.001) associated with increased mortality. Patients with all four covariates showed a 27-fold increased likelihood of death (P=0.00002). Chronic graft histopathology, rejection rates, and death-censored graft survival were not significantly different between groups.
Conclusion: The SD-rATG induction improves the 3-year renal function in recipients of deceased donor kidneys. This benefit, along with possibly improved patient survival and fewer infections suggest that how rATG is administered may impact its efficacy and safety.
Trial registration: ClinicalTrials.gov NCT00556933.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
- Kasiske BL, Gaston RS, Gourishankar S, et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005; 5: 1405.
- Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
- Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
- Haririan A, Kiangkitiwan B, Kukuruga D, et al. The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant 2009; 9: 2758.
- Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
- Kedainis RL, Koch MJ, Brennan DC, et al. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant 2009; 9: 812.
- Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
- Mao Q, Terasaki PI, Cai J, et al. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation 2007; 83: 54.
- Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82: 1153.
- Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
- Troppmann C, Gruessner RW, Matas AJ, et al. Results with renal transplants performed after previous solitary pancreas transplants. Transplant Proc 1994; 26: 448.
- Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010; 10: 2066.
- Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int 2009; 22: 38.
- Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
- Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
- Matas AJ, Granger D, Kaufman DB, et al. Steroid minimization for sirolimus-treated renal transplant recipients. Clin Transplant 2011; 25: 457.
- Srivastava A, Muruganandham K, Vinodh PB, et al. Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors. Int Urol Nephrol 2010; 42: 279.
- Miles CD, Skorupa JY, Sandoz JP, et al. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus. Clin Transplant 2011; 25: 898.
- Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int 2011; 24: 1216.
- Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation 2012; 94: 547.
- Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
- Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10: 1385.
- Bunnapradist S, Vincenti F. Transplantation: to convert or not to convert: lessons from the CONVERT trial. Nat Rev Nephrol 2009; 5: 371.
- Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
- Matas AJ, Kandaswamy R, Humar A, et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004; 240: 510.
- Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients—an interim analysis. Am J Transplant 2005; 5: 1529.
- Suszynski TM, Gillingham KJ, Rizzari MD, et al. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. Am J Transplant 2013; 13: 961.
- Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460.
- Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798.
- Kaden J, May G, Volp A, et al. Improved long-term survival after intra-operative single high-dose ATG-Fresenius induction in renal transplantation: a single centre experience. Ann Transplant 2009; 14: 7.
- Kyllonen LE, Eklund BH, Pesonen EJ, et al. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 2007; 84: 75.
- Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505.
- Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502.
- Gore SM. Graft survival after renal transplantation: agenda for analysis. Kidney Int 1983; 24: 516.
- Winer BJ, Brown DR, Michels KM. Statistical principles in experimental design. 3rd ed New York: McGraw-Hill; 1991: xiii.
- Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008; 85: 1391.
- Metchnikoff E. Recherches sur l’influence de l’organisme sur les toxins: toxine tetanique et leukocytes. Ann Inst Pasteur 1898; 12: 263.
- Woodruff M, Forman B. Effect of antilymphocytic serum on suspensions of lymphocytes in vitro. Nature 1951; 168: 35.
- Monaco AP, Abbott WM, Othersen HB, et al. Antiserum to lymphocytes: prolonged survival of canine renal allografts. Science 1966; 153: 1264.
- Najarian JS, Simmons RL, Gewurz H, et al. Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man. Ann Surg 1969; 170: 617.
- Starzl TE, Marchioro TL, Porter KA, et al. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 1967; 124: 301.
- Kaden J, Strobelt V, May G. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation. Transplant Proc 1998; 30: 4011.
- Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505.
- Stevens RB, Lane JT, Boerner BP, et al. Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clin Transplant 2012; 26: 123.
- Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
- Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
- Ducloux D, Courivaud C, Bamoulid J, et al. Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. J Am Soc Nephrol 2010; 21: 868.
- Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308: 307.
- Ducloux D, Challier B, Saas P, et al. CD4 cell lymphopenia and atherosclerosis in renal transplant recipients. J Am Soc Nephrol 2003; 14: 767.
- Tse K, Tse H, Sidney J, et al. T cells in atherosclerosis. Int Immunol 2013; 25: 615.
- Aukrust P, Yndestad A, Sandberg WJ, et al. T cells in coronary artery disease: different effects of different T-cell subsets. J Am Coll Cardiol 2007; 50: 1459.
- Sureshkumar KK, Thai NL, Hussain SM, et al. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression. Transplantation 2012; 93: 799.
- Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
- LaCorcia G, Swistak M, Lawendowski C, et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009; 87: 966.
- Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387.
- Mehrabi A, Mood Zh A, Sadeghi M, et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant 2007; 22: viii54.
- Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009; 20: 1149.
- Mueller TF, Reeve J, Jhangri GS, et al. The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function. Am J Transplant 2008; 8: 78.
- Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7: 2712.
- Gaber AO, Monaco AP, Russell JA, et al. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010; 70: 691.
- Mueller TF. Mechanisms of action of thymoglobulin. Transplantation 2007; 84: S5.
- Urbanova M, Brabcova I, Girmanova E, et al. Differential regulation of the nuclear factor-kappaB pathway by rabbit antithymocyte globulins in kidney transplantation. Transplantation 2012; 93: 589.
- Sanz AB, Sanchez-Nino MD, Ramos AM, et al. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254.
- Rangan GK, Wang Y, Tay YC, et al. Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999; 56: 118.
- Stevens RB, Platt JL. The pathogenesis of hyperacute xenograft rejection. Am J Kidney Dis 1992; 20: 414.
- Stevens RB, Wang YL, Kaji H, et al. Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival. Transplant Proc 1993; 25 (1 Pt 1): 382.
- Navarro FP, Fares RP, Sanchez PE, et al. Brain heparanase expression is up-regulated during postnatal development and hypoxia-induced neovascularization in adult rats. J Neurochem 2008; 105: 34.
- Chappell D, Jacob M, Rehm M, et al. Heparinase selectively sheds heparan sulphate from the endothelial glycocalyx. Biol Chem 2008; 389: 79.
- Miller JD, Clabaugh SE, Smith DR, et al. Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. Immunol Cell Biol 2012; 90: 159.
- Downie GH, Ryan US, Hayes BA, et al. Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro. Am J Respir Cell Mol Biol 1992; 7: 58.
- Li J, Gyorffy S, Lee S, et al. Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro. Inflammation 1996; 20: 361.
- Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
- Solez K, Colvin RB, Racusen LC, et al. Banff ’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 2007; 7: 518.
- Nyberg SL, Matas AJ, Kremers WK, et al. Improved scoring system to assess adult donors for cadaver renal transplantation. Am J Transplant 2003; 3: 715.
- Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. Springer Verlag; 2009.
Source: PubMed